Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04561089 · ClinicalTrials.gov registry record
Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 763
- Enrollment target
NCT04561089: Completed study, sponsored by Illumina.
NCT04561089 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 763 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04561089 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 763 participants
- Enrollment target
Study Summary
"This is a prospective, multi-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one nasal swab will be tested with an EUA approved COVID test. The other nasal swab sample will be stored and a subset (approximately 250 specimens) will be tested with the COVIDSeq Test. Results of all testing will be provided to the sponsor for statistical analysis. Positive results from COVIDSeq Test using saliva and/or the comparator EUA test will be provided to subjects so participants can be referred for further evaluation (outside the study). No medical treatment, guidance on treatment decisions, nor medical care will be provided. "
Interventions
- DIAGNOSTIC_TEST COVIDSeq Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 763 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2021-02-28 |
What the finished NCT04561089 record still lists
NCT04561089 is an observational study that tracks outcomes without assigning an intervention. The registered 763 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which COVIDSeq Test is the first listed.
NCT04561089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04561089 about?
NCT04561089 is a clinical study titled "Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel". "This is a prospective, multi-center specimen collection study. Subjects 18 years of age or older who do not have symptoms of COVID-19 will be enrolled. Two nasal swab samples and one saliva sample will be collected from each subject. The saliva sample will be tested with the COVIDSeq Test and one n...
What is the current status of trial NCT04561089?
This trial is currently completed. The enrollment target is 763 participants. The study started on 2020-02-13. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT04561089?
The interventions under investigation include: COVIDSeq Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04561089?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT05579366 · 764 participants · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- NCT06419374 · 762 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- NCT03789552 · 765 participants · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI